Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings in Brief: Trex Medical

This article was originally published in The Gray Sheet

Executive Summary

Trex Medical: Registration statement filed with the SEC covers a secondary offering of 4.5 mil. shares of common stock. Proceeds will be used to finance the mammography and general-purpose x-ray system manufacturer's entrance into the dental x-ray market through the acquisition of Paris-based Trophy Radiologie, for which a letter of intent was announced Jan. 6 ("The Gray Sheet" Jan. 12, In Brief). Trophy, which generated $70 mil. in sales for fiscal year 1997 (ended Aug. 31), markets the RVG series of digital x-ray systems to dentists, orthodontists and periodontists. Specific terms of the deal were not disclosed. Offering underwriters Salomon Smith Barney and Lehman Brothers "are expected to be granted a 30-day overallotment option to purchase an additional 675,000 shares," Trex states...

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts